Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

Yasuhiro Kaga; Yu Sunakawa; Yutaro Kubota; Teppei Tagawa; Taikan Yamamoto; Toshikazu Ikusue; Yu Uto; Kouichirou Miyashita; Hirokazu Toshima; Kouji Kobayashi; Atsushi Hisamatsu; Wataru Ichikawa; Takashi Sekikawa; Ken Shimada; Yasutsuna Sasaki

doi:10.18632/oncotarget.12007

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

Yasuhiro Kaga, Yu Sunakawa _, Yutaro Kubota, Teppei Tagawa, Taikan Yamamoto, Toshikazu Ikusue, Yu Uto, Kouichirou Miyashita, Hirokazu Toshima, Kouji Kobayashi, Atsushi Hisamatsu, Wataru Ichikawa, Takashi Sekikawa, Ken Shimada and Yasutsuna Sasaki

PDF | HTML | How to cite

Oncotarget. 2016; 7:67314-67320. https://doi.org/10.18632/oncotarget.12007

Metrics: PDF 1981 views | HTML 1970 views | ?

Abstract

Yasuhiro Kaga1,*, Yu Sunakawa1,*, Yutaro Kubota2, Teppei Tagawa2, Taikan Yamamoto1, Toshikazu Ikusue1, Yu Uto1, Kouichirou Miyashita1, Hirokazu Toshima3, Kouji Kobayashi3, Atsushi Hisamatsu3, Wataru Ichikawa4, Takashi Sekikawa4, Ken Shimada3, Yasutsuna Sasaki2

1Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan

2Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan

3Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan

4Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan

*These authors contributed equally to this work

Correspondence to:

Yu Sunakawa, email: [email protected]

Keywords: pancreatic cancer, FOLFIRINOX, early tumor shrinkage

Received: July 10, 2016 Accepted: September 06, 2016 Published: September 13, 2016

ABSTRACT

There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 patients with advanced pancreatic cancer treated with FOLFIRINOX therapy. The association of ETS with progression-free survival (PFS) and overall survival (OS) was evaluated but also we addressed to the correlation between outcomes and DpR. ETS was defined as a reduction ≥ 20% of target lesions’ diameters measured at 6 to 8 weeks from treatment start. DpR was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Among 47 evaluable patients for the ETS, 12 (25.5%) patients experienced ETS. The ETS was significantly associated with better PFS (9.0 vs. 4.2 months) as well as OS (24.0 vs. 9.1 months); moreover, the association had a statistically significance for PFS but a strong trend for OS in multivariate analysis. The DpR was statistically significantly but weakly associated with OS. In conclusion, this is the first report that the early response to chemotherapy may predict favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12007

Publication Alerts

Research Papers:

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

Abstract